How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
This project is currently in its early development stage. If you encounter any issues, feel free to create an issue for feedback or directly submit a PR to fix it.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback